Indemakitug is under clinical development by Elixiron Immunotherapeutics and currently in Phase I for Hemophagocytic Lymphohistiocytosis. According to GlobalData, Phase I drugs for Hemophagocytic Lymphohistiocytosis have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Indemakitug’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Indemakitug overview

EI-001 is under development for the treatment of Vitiligo and hemophagocytic lymphohistiocytosis. It is administered through intravenous route. It was also under development for the treatment of chronic hepatitis B infection. It acts by targeting interferon gamma (IFN-gamma)

Elixiron Immunotherapeutics overview

Elixiron Immunotherapeutics (Elixiron) is a clinical stage company which advances in translational medicine to identify targets from clinical observations, and various drug modalities from a proprietary single human B cell cloning platform to develop

For a complete picture of Indemakitug’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.